Drug combination found to extend lifespan by 30 per cent “INDEPENDENT”

Breakthrough Drug Duo Prolongs Mouse Lifespan by 30%

A pioneering study from Germany’s Max Planck Institute for Biology of Aging has unveiled that a combination of two existing cancer medications—rapamycin and trametinib—can extend the lifespan of mice by approximately 30%. This discovery offers promising insights into potential anti-aging therapies for humans.

The Study’s Findings

In the research, mice treated with rapamycin alone experienced a lifespan increase of 15–20%, while those administered trametinib saw a 5–10% extension. However, the most significant results were observed when both drugs were used together, leading to a 30% increase in lifespan. Beyond longevity, the treated mice exhibited improved health markers, including reduced inflammation and slower tumor development.

Mechanisms of Action

Rapamycin functions by inhibiting the mTOR pathway, which regulates cell growth and metabolism. Trametinib, on the other hand, targets the MEK1/2 enzymes involved in cell division and survival. Together, these drugs appear to complement each other, enhancing their individual effects and mitigating potential side effects.

This study marks a significant step forward in aging research, highlighting the potential of existing medications to promote healthier aging. As research progresses, there is hope that similar approaches could be developed for human use, offering new avenues for enhancing quality of life in later years.